Condition
Non-Active Secondary Progressive Multiple Sclerosis
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Unknown1
Suspended1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06890923Phase 2RecruitingPrimary
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
NCT06802328UnknownPrimary
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
NCT06677710Phase 1Suspended
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Showing all 3 trials